{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T01:01:53Z","timestamp":1773795713644,"version":"3.50.1"},"reference-count":75,"publisher":"The Endocrine Society","issue":"8","license":[{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012264","name":"NIH","doi-asserted-by":"publisher","award":["R01 DK088114"],"award-info":[{"award-number":["R01 DK088114"]}],"id":[{"id":"10.13039\/501100012264","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012264","name":"NIH","doi-asserted-by":"publisher","award":["UL1TR000433"],"award-info":[{"award-number":["UL1TR000433"]}],"id":[{"id":"10.13039\/501100012264","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012264","name":"NIH","doi-asserted-by":"publisher","award":["P30 DK089503"],"award-info":[{"award-number":["P30 DK089503"]}],"id":[{"id":"10.13039\/501100012264","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012264","name":"NIH","doi-asserted-by":"publisher","award":["DK034933"],"award-info":[{"award-number":["DK034933"]}],"id":[{"id":"10.13039\/501100012264","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Partial lipodystrophy (PL) is a rare disease characterized by selective loss of subcutaneous fat.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To evaluate changes in apolipoproteins, hepatokines, hormones, appetite regulators, and inflammatory markers in patients with PL treated with leptin, assess postprandial metabolism and 24-hour dynamics, and identify predictors of hepatic and metabolic response to therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We studied 19 subjects from our previous clinical study (NCT01679197), which investigated the effect of leptin on metabolic dysfunction-associated steatohepatitis associated with PL. A mixed-meal test was performed in a subgroup of 14 patients, and paired 24-hour frequent sampling with standardized meals was completed in 5 individuals.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Leptin treatment led to reductions in apolipoproteins B, CII, CIII, and E (P &amp;lt; .05). Levels of ANGPTL3 tended to decrease after leptin treatment (P = .079). The mixed-meal test revealed significant reductions in triglyceride area under the curve (P = .017) and glucose excursions at several postmeal time points (P &amp;lt; .05). The immediate GIP secretion in response to a meal attenuated after leptin therapy (P = .005 at 60\u2005minutes). Ghrelin levels showed an increase after leptin administration. The response to leptin treatment was associated with several factors, including baseline carbohydrate intake, leptin and triglyceride levels and triglyceride-rich apolipoproteins, and changes in triglyceride-rich apolipoproteins (P &amp;lt; .05 for all). Changes in IGF-1 levels were correlated with improvements in metabolic and liver parameters (P &amp;lt; .05).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Leptin therapy modulates lipid metabolism, postprandial glucose regulation, and appetite signaling in patients with PL, with responses associated with metabolic parameters and carbohydrate intake.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/jendso\/bvaf067","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T19:56:17Z","timestamp":1746647777000},"source":"Crossref","is-referenced-by-count":2,"title":["Changes After Leptin Administration in Partial Lipodystrophy and Factors Associated With Hepatic and Metabolic Response"],"prefix":"10.1210","volume":"9","author":[{"given":"Baris","family":"Akinci","sequence":"first","affiliation":[{"name":"Caswell Diabetes Institute and Division of Metabolism, Endocrinology & Diabetes, University of Michigan , Ann Arbor, MI 48109 ,","place":["USA"]},{"name":"Technological Research Program, Izmir Biomedicine and Genome Center & Depark, Dokuz Eylul University Health Campus , 35330 Izmir ,","place":["Turkey"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nevin","family":"Ajluni","sequence":"additional","affiliation":[{"name":"Caswell Diabetes Institute and Division of Metabolism, Endocrinology & Diabetes, University of Michigan , Ann Arbor, MI 48109 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rasimcan","family":"Meral","sequence":"additional","affiliation":[{"name":"Caswell Diabetes Institute and Division of Metabolism, Endocrinology & Diabetes, University of Michigan , Ann Arbor, MI 48109 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam Hugh","family":"Neidert","sequence":"additional","affiliation":[{"name":"Caswell Diabetes Institute and Division of Metabolism, Endocrinology & Diabetes, University of Michigan , Ann Arbor, MI 48109 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Foss","family":"Freitas","sequence":"additional","affiliation":[{"name":"Caswell Diabetes Institute and Division of Metabolism, Endocrinology & Diabetes, University of Michigan , Ann Arbor, MI 48109 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donatella","family":"Gilio","sequence":"additional","affiliation":[{"name":"Caswell Diabetes Institute and Division of Metabolism, Endocrinology & Diabetes, University of Michigan , Ann Arbor, MI 48109 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hari","family":"Conjeevaram","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, University of Michigan , Ann Arbor, MI 48109 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9171-1144","authenticated-orcid":false,"given":"Elif Arioglu","family":"Oral","sequence":"additional","affiliation":[{"name":"Caswell Diabetes Institute and Division of Metabolism, Endocrinology & Diabetes, University of Michigan , Ann Arbor, MI 48109 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2025,5,7]]},"reference":[{"issue":"2","key":"2025062620201335500_bvaf067-B1","doi-asserted-by":"crossref","first-page":"310","DOI":"10.4158\/EP09154.RA","article-title":"Clinical classification and treatment of congenital and acquired lipodystrophy","volume":"16","author":"Chan","year":"2010","journal-title":"Endocr Pract"},{"issue":"12","key":"2025062620201335500_bvaf067-B2","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1210\/jc.2016-2466","article-title":"The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline","volume":"101","author":"Brown","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2025062620201335500_bvaf067-B3","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s11892-018-1099-9","article-title":"Phenotypic and genetic characteristics of lipodystrophy: pathophysiology, metabolic abnormalities, and comorbidities","volume":"18","author":"Akinci","year":"2018","journal-title":"Curr Diab Rep"},{"issue":"2","key":"2025062620201335500_bvaf067-B4","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ecl.2004.03.003","article-title":"Lipodystrophies: rare disorders causing metabolic syndrome","volume":"33","author":"Garg","year":"2004","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"11","key":"2025062620201335500_bvaf067-B5","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1210\/jc.2011-1159","article-title":"Clinical review#: lipodystrophies: genetic and acquired body fat disorders","volume":"96","author":"Garg","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2025062620201335500_bvaf067-B6","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1056\/NEJMra025261","article-title":"Acquired and inherited lipodystrophies","volume":"350","author":"Garg","year":"2004","journal-title":"N Engl J Med"},{"issue":"1","key":"2025062620201335500_bvaf067-B7","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4158\/endp.19.1.v767575m65p5mr06","article-title":"The clinical approach to the detection of lipodystrophy\u2014an AACE consensus statement","volume":"19","author":"Handelsman","year":"2013","journal-title":"Endocr Pract"},{"key":"2025062620201335500_bvaf067-B8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.metabol.2017.04.010","article-title":"Clinical presentations, metabolic abnormalities and end-organ complications in patients with familial partial lipodystrophy","volume":"72","author":"Akinci","year":"2017","journal-title":"Metabolism"},{"issue":"9","key":"2025062620201335500_bvaf067-B9","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.metabol.2015.06.004","article-title":"Acquired partial lipodystrophy is associated with increased risk for developing metabolic abnormalities","volume":"64","author":"Akinci","year":"2015","journal-title":"Metabolism"},{"issue":"1","key":"2025062620201335500_bvaf067-B10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-2001-12925","article-title":"Nonalcoholic steatohepatitis: definition and pathology","volume":"21","author":"Brunt","year":"2001","journal-title":"Semin Liver Dis"},{"issue":"1","key":"2025062620201335500_bvaf067-B11","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/hep.1840110114","article-title":"The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years","volume":"11","author":"Powell","year":"1990","journal-title":"Hepatology"},{"issue":"5","key":"2025062620201335500_bvaf067-B12","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/cen.13311","article-title":"Spectrum of disease associated with partial lipodystrophy: lessons from a trial cohort","volume":"86","author":"Ajluni","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"2025062620201335500_bvaf067-B13","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1210\/jc.2018-02730","article-title":"Comorbidities and survival in patients with lipodystrophy: an international chart review study","volume":"104","author":"Akinci","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2025062620201335500_bvaf067-B14","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s11892-018-1100-7","article-title":"Update on therapeutic options in lipodystrophy","volume":"18","author":"Akinci","year":"2018","journal-title":"Curr Diab Rep"},{"issue":"8","key":"2025062620201335500_bvaf067-B15","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1056\/NEJMoa012437","article-title":"Leptin-replacement therapy for lipodystrophy","volume":"346","author":"Oral","year":"2002","journal-title":"N Engl J Med"},{"issue":"3","key":"2025062620201335500_bvaf067-B16","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s12020-018-1589-1","article-title":"Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy","volume":"60","author":"Brown","year":"2018","journal-title":"Endocrine"},{"issue":"3","key":"2025062620201335500_bvaf067-B17","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s12020-019-01862-8","article-title":"Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophy","volume":"64","author":"Oral","year":"2019","journal-title":"Endocrine"},{"issue":"7","key":"2025062620201335500_bvaf067-B18","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.medj.2021.04.001","article-title":"Metreleptin therapy for nonalcoholic steatohepatitis: open-label therapy interventions in two different clinical settings","volume":"2","author":"Akinci","year":"2021","journal-title":"Med"},{"issue":"6704","key":"2025062620201335500_bvaf067-B19","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/27376","article-title":"Leptin and the regulation of body weight in mammals","volume":"395","author":"Friedman","year":"1998","journal-title":"Nature"},{"issue":"1","key":"2025062620201335500_bvaf067-B20","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2337\/db15-0973","article-title":"Knockdown of GLP-1 receptors in vagal afferents affects normal food intake and glycemia","volume":"65","author":"Krieger","year":"2016","journal-title":"Diabetes"},{"issue":"8","key":"2025062620201335500_bvaf067-B21","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1210\/js.2019-00103","article-title":"Advanced lipoprotein analysis shows atherogenic lipid profile that improves after metreleptin in patients with lipodystrophy","volume":"3","author":"Kinzer","year":"2019","journal-title":"J Endocr Soc"},{"issue":"3","key":"2025062620201335500_bvaf067-B22","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.bbrc.2004.08.024","article-title":"Leptin and insulin down-regulate angiopoietin-like protein 3, a plasma triglyceride-increasing factor","volume":"322","author":"Shimamura","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"2025062620201335500_bvaf067-B23","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jacl.2017.02.002","article-title":"Metreleptin therapy lowers plasma angiopoietin-like protein 3 in patients with generalized lipodystrophy","volume":"11","author":"Muniyappa","year":"2017","journal-title":"J Clin Lipidol"},{"issue":"2","key":"2025062620201335500_bvaf067-B24","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ecl.2012.04.017","article-title":"Metabolic actions of insulin-like growth factor-I in normal physiology and diabetes","volume":"41","author":"Clemmons","year":"2012","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"7","key":"2025062620201335500_bvaf067-B25","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/j.1478-3231.2010.02428.x","article-title":"Insulin-like growth factor-I and the liver","volume":"31","author":"Bonefeld","year":"2011","journal-title":"Liver Int"},{"issue":"6","key":"2025062620201335500_bvaf067-B26","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"issue":"10","key":"2025062620201335500_bvaf067-B27","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.2337\/dc18-0978","article-title":"\u201cFat shadows\u201d from DXA for the qualitative assessment of lipodystrophy: when a picture is worth a thousand numbers","volume":"41","author":"Meral","year":"2018","journal-title":"Diabetes Care"},{"issue":"10","key":"2025062620201335500_bvaf067-B28","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S0026-0495(97)90222-5","article-title":"Relationship between resting metabolic rate and the composition of the fat-free mass","volume":"46","author":"Sparti","year":"1997","journal-title":"Metabolism"},{"issue":"1","key":"2025062620201335500_bvaf067-B29","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/cen.12980","article-title":"Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy","volume":"85","author":"Chan","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2025062620201335500_bvaf067-B30","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/MOL.0b013e32832d4a33","article-title":"Inherited lipodystrophies and hypertriglyceridemia","volume":"20","author":"Simha","year":"2009","journal-title":"Curr Opin Lipidol"},{"key":"2025062620201335500_bvaf067-B31","volume-title":"Endotext","author":"Akinci","year":"2024"},{"issue":"6","key":"2025062620201335500_bvaf067-B32","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1093\/ajcn\/81.6.1405","article-title":"Severely dysregulated disposal of postprandial triacylglycerols exacerbates hypertriacylglycerolemia in HIV lipodystrophy syndrome","volume":"81","author":"Sekhar","year":"2005","journal-title":"Am J Clin Nutr"},{"issue":"3","key":"2025062620201335500_bvaf067-B33","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1053\/j.gastro.2013.11.049","article-title":"Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease","volume":"146","author":"Lambert","year":"2014","journal-title":"Gastroenterology"},{"issue":"3","key":"2025062620201335500_bvaf067-B34","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2337\/diabetes.52.3.675","article-title":"Nocturnal and postprandial free fatty acid kinetics in normal and type 2 diabetic subjects: effects of insulin sensitization therapy","volume":"52","author":"Miles","year":"2003","journal-title":"Diabetes"},{"key":"2025062620201335500_bvaf067-B35","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.metabol.2019.04.014","article-title":"The incretin system in healthy humans: the role of GIP and GLP-1","volume":"96","author":"Holst","year":"2019","journal-title":"Metabolism"},{"issue":"6","key":"2025062620201335500_bvaf067-B36","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"issue":"6778","key":"2025062620201335500_bvaf067-B37","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/35007534","article-title":"Central nervous system control of food intake","volume":"404","author":"Schwartz","year":"2000","journal-title":"Nature"},{"issue":"4","key":"2025062620201335500_bvaf067-B38","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2337\/dc23-1614","article-title":"Efficacy and safety of glucagon-like peptide 1 agonists in a retrospective study of patients with familial partial lipodystrophy","volume":"47","author":"Foss-Freitas","year":"2024","journal-title":"Diabetes Care"},{"issue":"4","key":"2025062620201335500_bvaf067-B39","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1111\/dom.16175","article-title":"Safety and effectiveness in an uncontrolled setting of glucagon-like-peptide-1 receptor agonists in patients with familial partial lipodystrophy: real-life experience from a national reference network","volume":"27","author":"Lamothe","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"2025062620201335500_bvaf067-B40","first-page":"756","article-title":"Metabolic improvements with tirzepatide in lipodystrophy: a novel option?","volume":"48","author":"Meral","year":"2025","journal-title":"Diabetes Care"},{"issue":"7","key":"2025062620201335500_bvaf067-B41","doi-asserted-by":"crossref","first-page":"e134359","DOI":"10.1172\/jci.insight.134359","article-title":"Leptin receptor-expressing nucleus tractus solitarius neurons suppress food intake independently of GLP1 in mice","volume":"5","author":"Cheng","year":"2020","journal-title":"JCI Insight"},{"issue":"4","key":"2025062620201335500_bvaf067-B42","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.metabol.2006.11.010","article-title":"Long-term efficacy of leptin replacement in patients with dunnigan-type familial partial lipodystrophy","volume":"56","author":"Park","year":"2007","journal-title":"Metabolism"},{"issue":"1","key":"2025062620201335500_bvaf067-B43","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00125-009-1502-9","article-title":"Efficacy of leptin therapy in the different forms of human lipodystrophy","volume":"53","author":"Chong","year":"2010","journal-title":"Diabetologia"},{"issue":"6","key":"2025062620201335500_bvaf067-B44","doi-asserted-by":"crossref","first-page":"922","DOI":"10.4158\/EP11229.OR","article-title":"Clinical effects of long-term metreleptin treatment in patients with lipodystrophy","volume":"17","author":"Chan","year":"2011","journal-title":"Endocr Pract"},{"issue":"5","key":"2025062620201335500_bvaf067-B45","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1210\/jc.2014-4491","article-title":"Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin","volume":"100","author":"Diker-Cohen","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025062620201335500_bvaf067-B46","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1210\/jc.2011-2229","article-title":"Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety","volume":"97","author":"Simha","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2025062620201335500_bvaf067-B47","doi-asserted-by":"crossref","first-page":"324","DOI":"10.4158\/EP09155.RA","article-title":"Rationale for leptin-replacement therapy for severe lipodystrophy","volume":"16","author":"Oral","year":"2010","journal-title":"Endocr Pract"},{"issue":"4","key":"2025062620201335500_bvaf067-B48","doi-asserted-by":"crossref","first-page":"e1739","DOI":"10.1210\/clinem\/dgab760","article-title":"Endogenous leptin concentrations poorly predict metreleptin response in patients with partial lipodystrophy","volume":"107","author":"Meral","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2025062620201335500_bvaf067-B49","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1111\/dom.14726","article-title":"Therapeutic indications and metabolic effects of metreleptin in patients with lipodystrophy syndromes: real-life experience from a national reference network","volume":"24","author":"Mosbah","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"2025062620201335500_bvaf067-B50","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1542\/peds.98.2.201","article-title":"Serum leptin in children with obesity: relationship to gender and development","volume":"98","author":"Hassink","year":"1996","journal-title":"Pediatrics"},{"issue":"3","key":"2025062620201335500_bvaf067-B51","first-page":"659","article-title":"Efficacy and safety of metreleptin in patients with partial lipodystrophy: lessons from an expanded access program","volume":"7","author":"Ajluni","year":"2016","journal-title":"J Diabetes Metab"},{"issue":"5","key":"2025062620201335500_bvaf067-B52","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J Clin Invest"},{"issue":"5","key":"2025062620201335500_bvaf067-B53","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/ajg.2013.95","article-title":"The Western dietary pattern is prospectively associated with nonalcoholic fatty liver disease in adolescence","volume":"108","author":"Oddy","year":"2013","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"2025062620201335500_bvaf067-B54","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/ejcn.2014.297","article-title":"Dietary patterns are associated with prevalence of fatty liver disease in adults","volume":"69","author":"Jia","year":"2015","journal-title":"Eur J Clin Nutr"},{"issue":"3","key":"2025062620201335500_bvaf067-B55","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.cmet.2018.01.005","article-title":"An integrated understanding of the rapid metabolic benefits of a carbohydrate-restricted diet on hepatic steatosis in humans","volume":"27","author":"Mardinoglu","year":"2018","journal-title":"Cell Metab"},{"issue":"3","key":"2025062620201335500_bvaf067-B56","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s001250050686","article-title":"Carbohydrate intake and short-term regulation of leptin in humans","volume":"40","author":"Jenkins","year":"1997","journal-title":"Diabetologia"},{"issue":"12","key":"2025062620201335500_bvaf067-B57","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1038\/nn.2977","article-title":"Leptin regulates the reward value of nutrient","volume":"14","author":"Domingos","year":"2011","journal-title":"Nat Neurosci"},{"issue":"8","key":"2025062620201335500_bvaf067-B58","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1172\/JCI95476","article-title":"Metreleptin-mediated improvements in insulin sensitivity are independent of food intake in humans with lipodystrophy","volume":"128","author":"Brown","year":"2018","journal-title":"J Clin Invest"},{"issue":"11","key":"2025062620201335500_bvaf067-B59","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.cmet.2022.09.020","article-title":"Leptin increases hepatic triglyceride export via a vagal mechanism in humans","volume":"34","author":"Metz","year":"2022","journal-title":"Cell Metab"},{"issue":"9319","key":"2025062620201335500_bvaf067-B60","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/S0140-6736(02)08655-5","article-title":"Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study","volume":"359","author":"Sandhu","year":"2002","journal-title":"Lancet"},{"issue":"4","key":"2025062620201335500_bvaf067-B61","doi-asserted-by":"crossref","first-page":"768","DOI":"10.2337\/dc11-1833","article-title":"The association between IGF-I and insulin resistance: a general population study in Danish adults","volume":"35","author":"Friedrich","year":"2012","journal-title":"Diabetes Care"},{"issue":"10","key":"2025062620201335500_bvaf067-B62","doi-asserted-by":"crossref","first-page":"E1640","DOI":"10.1210\/jc.2011-1227","article-title":"Nonalcoholic fatty liver disease is associated with low circulating levels of insulin-like growth factor-I","volume":"96","author":"Arturi","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2025062620201335500_bvaf067-B63","doi-asserted-by":"crossref","first-page":"155694","DOI":"10.1016\/j.metabol.2023.155694","article-title":"Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: a multicenter observational study","volume":"148","author":"Valenzuela-Vallejo","year":"2023","journal-title":"Metabolism"},{"issue":"2","key":"2025062620201335500_bvaf067-B64","doi-asserted-by":"crossref","first-page":"e520","DOI":"10.1210\/clinem\/dgaa792","article-title":"Relationship of IGF-1 and IGF-binding proteins to disease severity and glycemia in nonalcoholic fatty liver disease","volume":"106","author":"Stanley","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025062620201335500_bvaf067-B65","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1038\/ctg.2016.72","article-title":"The association between IGF-1 levels and the histologic severity of nonalcoholic fatty liver disease","volume":"8","author":"Dichtel","year":"2017","journal-title":"Clin Transl Gastroenterol"},{"issue":"4","key":"2025062620201335500_bvaf067-B66","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1046\/j.1365-2265.1998.00557.x","article-title":"The IGF-I\/IGFBP system in congenital partial lipodystrophy","volume":"49","author":"Janssen","year":"1998","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"2025062620201335500_bvaf067-B67","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1210\/jc.2018-02289","article-title":"Thyroid abnormalities in patients with extreme insulin resistance syndromes","volume":"104","author":"Kushchayeva","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2025062620201335500_bvaf067-B68","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1210\/endo.139.9.6206","article-title":"Leptin is a potent stimulator of spontaneous pulsatile growth hormone (GH) secretion and the GH response to GH-releasing hormone","volume":"139","author":"Tannenbaum","year":"1998","journal-title":"Endocrinology"},{"issue":"7","key":"2025062620201335500_bvaf067-B69","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1038\/s41366-021-00809-2","article-title":"Serum IGF1 and linear growth in children with congenital leptin deficiency before and after leptin substitution","volume":"45","author":"Beghini","year":"2021","journal-title":"Int J Obes (Lond)"},{"issue":"5","key":"2025062620201335500_bvaf067-B70","doi-asserted-by":"crossref","first-page":"696","DOI":"10.2337\/diab.42.5.696","article-title":"Trial of insulinlike growth factor I therapy for patients with extreme insulin resistance syndromes","volume":"42","author":"Kuzuya","year":"1993","journal-title":"Diabetes"},{"issue":"Suppl","key":"2025062620201335500_bvaf067-B71","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1016\/0168-8227(95)01084-Q","article-title":"Insulin-like growth factor I (rhIGF-I) as a therapeutic agent for hyperinsulinemic insulin-resistant diabetes mellitus","volume":"28","author":"Moses","year":"1995","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"2025062620201335500_bvaf067-B72","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1507\/endocrj.K06-014","article-title":"Long-term effects of recombinant human insulin-like growth factor I treatment on glucose and lipid metabolism and the growth of a patient with congenital generalized lipodystrophy","volume":"53","author":"Satoh","year":"2006","journal-title":"Endocr J"},{"issue":"12","key":"2025062620201335500_bvaf067-B73","doi-asserted-by":"crossref","first-page":"e821","DOI":"10.1016\/S2352-3018(19)30338-8","article-title":"Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial","volume":"6","author":"Stanley","year":"2019","journal-title":"Lancet HIV"},{"issue":"12","key":"2025062620201335500_bvaf067-B74","doi-asserted-by":"crossref","first-page":"e1542","DOI":"10.1210\/clinem\/dgad375","article-title":"Growth hormone administration improves nonalcoholic fatty liver disease in overweight\/obesity: a randomized trial","volume":"108","author":"Dichtel","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025062620201335500_bvaf067-B75","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2265.1995.tb02031.x","article-title":"Altered endogenous growth hormone secretory kinetics and diurnal GH-binding protein profiles in adults with chronic liver disease","volume":"43","author":"Cuneo","year":"1995","journal-title":"Clin Endocrinol (Oxf)"}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jes\/advance-article-pdf\/doi\/10.1210\/jendso\/bvaf067\/63104305\/bvaf067.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/9\/8\/bvaf067\/63104305\/bvaf067.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/9\/8\/bvaf067\/63104305\/bvaf067.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:20:26Z","timestamp":1750983626000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/doi\/10.1210\/jendso\/bvaf067\/8126663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,7]]},"references-count":75,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,6,9]]}},"URL":"https:\/\/doi.org\/10.1210\/jendso\/bvaf067","relation":{},"ISSN":["2472-1972"],"issn-type":[{"value":"2472-1972","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,5,7]]},"article-number":"bvaf067"}}